MANIPAL HOSPITALS EXPANDS ITS VACCINE PORTFOLIO WITH SPUTNIK V PILOT
The hospital chain is all set to roll out Sputnik V vaccine pilot along with Covishield and Covaxin
Chennai, 6th June 2021: Manipal Hospitals, India’s second largest multi-speciality hospital chain has been at the forefront of the vaccine drive in the country and aims to reach as many people as possible. Today, the hospital ch ain collaborates with Dr. Reddy’s Laboratories (”Dr. Reddy’s”) to add the Sputnik V vaccine pilot in its existing va ccine portfolio that comprises of Covishield and Covaxin. The roll out of the Sputnik V vaccine by Manipal Hospitals in Bengaluru is part of the limited pilot soft launch initiated by Dr. Reddy’s in Hyderabad last month.
Speaking about the new development, Mr Karthik Rajagopal, COO, Manipal Health Enterprises Pvt Ltd, “We are delighted to state that Manipal Hospitals is well prepared to roll out the Sputnik V vaccine pilot. Manipal Hosp itals has worked closely with Dr. Reddy’s to create the state-of-the-art infrastructure to maintain Sputnik V vac cine. The hospital chain has successfully conducted vaccination drives with Covishield and Covaxin across the country till date and will continue the efforts along with the new addition of Sputnik V. We are expecting the vaccine to be available for the public soon in the latter half of the month.”
Addressing the need of the hour especially with the first batch of the Sputnik V vaccine directly transported f rom Russia, Manipal Hospitals has invested in creating a robust cold chain storage infrastructure as the vaccine needs to be stored in minus 18⁰ centigrade. Manipal Hospitals and Dr. Reddy’s took extensive efforts to ensure stringent cold chain maintenance as per the required guidelines for the vaccine. The cold chain storage even has a real-time logger which records the temperature every second.
M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said: “We are pleased to collab orate with Manipal Ho spital in Bengaluru as we scale up our soft pilot launch of the Sput nik V vaccine in India and extend it to more cities ahead of the co mmercial launch later in June. In the upcoming months we hope to inoculate as many Indians as possible.”
About Manipal Hospitals:
As a pioneer in healthcare, Manipal Hospitals is India’s second largest multi-specialty healthcare providers trea ting over 4 million patients annually. With its recent acquisition of 100% stake in Columbia Asia Hospitals in In dia, the integrated organisation today has an enhanced pan-India footprint with 26 hospitals across 14 cities wi th 7,000+ beds with a talented pool of 4,000+ doctors and 10,000+ employees. Its focus is to develop an af ford able, high quality healthcare framework through its multispecialty and tertiary care delivery spectrum and fur ther extend it to out of hospital care. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe.
About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Thr ough its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Pro ducts – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets acro ss the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.
